We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic breast cancer is a stage of breast cancer where the disease has spread beyond the breast to other parts of the body. In this case, it specifically refers to hormone receptor-positive, HER2-negative types with gBRCA1/2 mutations.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.